inspiring canadians to live better.

healthing leaf

inspiring canadians to live better.

healthing leaf
get healthing in your inbox with the morning checkup and weekender newsletter!

moderna's mrna technology paves way for hiv vaccine

scientists hope that the technology, used in the covid-19 vaccine, will help the immune system recognize and neutralize the virus before it can attack the body.

by emma jones
published feb 09, 2022
last updated apr 26, 2024
read time 3 minute read
join the conversation
read time 3 minute read
join the conversation
moderna's mrna technology paves way for hiv vaccine
previously, moderna has pledged to use the mrna technology to target illnesses that have evaded the defence of vaccines. getty
a stage one clinical trial for a promising hiv vaccine is underway. the vaccine uses moderna’s mrna technology, first deployed in moderna’s covid-19 vaccine. in the clinical trial, 56 patients without hiv will undergo a series of vaccinations to test the safety and immune response of the vaccine, with vaccinations having already been administered at george washington university in washington, d.c. the goal is to help the immune system recognize and neutralize the virus before it can attack the white blood cells.
“the search for an hiv vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective hiv vaccine,” mark feinberg, m.d., ph.d., president and ceo of iavi, said in a statement.
currently, medications can achieve a state of viral suppression, which will stop the virus from being passed from a patient with hiv to someone without.
there were approximately 2,242 new cases of hiv were reported in canada in 2018, according to
the public health agency of canada, making it the fourth consecutive year that hiv transmission rates had increased. it is estimated that approximately 62,050 people in canada live with hiv today.  

related stories

lessons learned, mistakes repeated: from hiv/aids to covid-19
for many people, covid made us aware of the work of infectious-disease practitioners for the first time, but their work has been unrelenting and urgent for decades.
systems using community engagement is just one way of avoiding public health mistakes. getty

as told to: 'being hiv-positive enabled me to find a real passion and life purpose'
christian hui, a toronto-based hiv+ activist and social worker, shares his story of triumph over racism, xenophobia and homophobia.
why haven’t governments around the world come together to bring about an overall solution? everyone in the world who is living with hiv should already have access to medication. getty
story continues below

a skeleton key to unlock millions of doors

developing a vaccine that can adequately protect the body from contracting hiv has proved elusive because the antigens that cause hiv mutate rapidly (to the tune of millions of different hiv strains), making it difficult to find a precise target that a single vaccine can use.

hiv variant seen in netherlands

researchers are also constantly discovering new forms of hiv, like the highly virulent version found in the netherlands in january. while this variant of hiv thankfully still responds to medication and isn’t considered a public health crisis, it highlights the need for preventative strategies if countries want to reach the unaids goal to eliminate hiv by 2030.
the aim of this vaccine is to prompt the body to develop a specific type of b-cell, a type of white blood cell, to make a complicated antibody capable of neutralizing the multitude of different types of strains that cause hiv.
this new vaccine strategy is, in a way, reverse-engineering a type of antibody that has been discovered in some patients who seem to have developed at least partial immunity to hiv. these individuals have produced an antibody dubbed ‘broadly neutralizing antibodies’ (bnabs), which target difficult-to-access markers on the virus that are similar across hiv strains. research into bnabs has been going on for more than 12 years.
story continues below
the task is to train b cells in the body to produce this very complex bnab, something that only one in every 300,000 naïve b cells are thought to be capable of. this is not going to be a one-shot process, as shepherding these b cells into mature, bnab production factories will require cutting edge precision. however, the results of a trial released in 2021 showed that at least the first step, prompting those b cells capable of producing bnabs to begin to develop into antibody machines, is possible.
the researchers turned to moderna’s mrna vaccine technology, according to a news release, because it allows them to quickly produce improvements to the vaccine that could “potentially shav[e] off years from typical vaccine development timelines.” this will allow researchers to spend more time on evaluating the clinical trials, to determine if each step is safe and developing the immune cells needed.
if successful, larger subsequent trials of the vaccine will be necessary, a process that takes years.

multiple players

the immunogens being tested in the development of the mrna were developed by researchers at scripps research and the international aids vaccine initiative (iavi), “a nonprofit scientific research organization that develops vaccines and antibodies for hiv, tuberculosis, emerging infectious diseases (including covid-19), and neglected diseases such as snakebite.” research is funded in part by the bill and melinda gates foundation.
story continues below
previously, moderna has pledged to use the mrna technology to target illnesses that have evaded the defence of vaccines.
“the uniquely challenging year of 2020 for all of society proved to be an extraordinary proof-of-concept period for moderna,” stéphane bancel, moderna’s chief executive officer, in a 2021 press release announcing new vaccine programs addressing seasonal flu, hiv and the nipah virus. “even as we have shown that our mrna-based vaccine can prevent covid-19, this has encouraged us to pursue more-ambitious development programs.”
emma jones is a multimedia editor with healthing. you can reach her at emjones@postmedia.com or on twitter @jonesyjourn
don’t miss a thing: sign-up for healthing’s newsletter
thank you for your support. if you liked this story, please send it to a friend. every share counts.

comments

postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. comments may take up to an hour for moderation before appearing on the site. we ask you to keep your comments relevant and respectful. we have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. visit our community guidelines for more information and details on how to adjust your email settings.